Skip to content

Does the eradication of endoparasites promote allergic disease?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN71058787
Enrollment
1600
Registered
2005-11-15
Start date
2005-04-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic disease, soil-transmitted helminths Skin and Connective Tissue Diseases Allergic disease

Interventions

The original study protocol used three-monthly single dose Mebendazole 500 mg over one year. After the first treatment round, investigators noticed low efficacy of this regime. Therefore, a treatment

Sponsors

University of Nottingham (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All primary and secondary school children (age 6-15) in four communes in Khanh Hoa province, central Viet Nam

Exclusion criteria

Exclusion criteria: Known allergy to Albendazole

Design outcomes

Primary

MeasureTime frame
Change in percent fall in peak expiratory flow after exercise challenge post gut worm treatment

Secondary

MeasureTime frame
Change in skin prick test hypersensitivity, host cytokine profiles, and allergic disease prevalence (skin examination for eczema and questionnaire-based for wheeze and rhinitis) post gut worm treatment

Countries

Viet Nam

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026